CTOs on the Move

GW Pharmaceuticals

www.gwpharm.com

 
GW was co-founded in 1998 by Dr. Geoffrey Guy and Dr. Brian Whittle, two well-known entrepreneurs in the UK biotech sector. In setting up GW, Drs. Guy and Whittle worked closely with both the UK Home Office and the UK`s medicines regulatory authority on establishing necessary licences and procedures so as to facilitate the progress of GW`s cannabinoid research program.
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.gwpharm.com
  • 5750 Fleet Street Suite 200
    Carlsbad, CA USA 92008
  • Phone: 760.795.2200

Executives

Name Title Contact Details

Similar Companies

MRXI Corporation

MRXI Corporation is a Downers Grove, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Novacea

Novacea, Inc. is a South San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Blade Therapeutics

Blade Therapeutics is a private biopharmaceutical company revolutionizing the treatment of fibrotic disease. Fibrosis, a pathologic process in which progressive scarring replaces functional tissue, drives the progression of several debilitating diseases. Uncontrolled, progressive fibrosis leads to organ dysfunction and failure, and potentially death. In the U.S., many millions of Americans are afflicted with a fibrosis-related disease, which may affect organs including the kidney, liver, lungs, skin, and eye.

Erytech

ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics to treat severe forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS® platform, which uses a novel technology to encapsulate drug substances inside red blood cells, ERYTECH is developing a pipeline of product candidates for patients with high unmet medical needs. ERYTECH`s primary focus is on the development of product candidates that target the altered metabolism of cancer cells by depriving them of amino acids necessary for their growth and survival. The Company`s lead product candidate, eryaspase, which consists of L-asparaginase encapsulated inside donor-derived red blood cells, targets the cancer cell`s altered asparagine and glutamine metabolism. Eryaspase is in Phase 3 clinical development for the treatment of second-line pancreatic cancer and in Phase 2 for the treatment of triple-negative breast cancer. ERYTECH is based in Lyon, France and Cambridge, MA, USA, and has manufacturing sites in Lyon, France, and Princeton, New Jersey, USA.

PharmaPix

PharmaPix is a Naperville, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.